Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.32 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166748 | 0.85 | TSHR (0.56) | TSHRHTR2CMAOBCYP2A6PNMT | |
| SCHEMBL2588514 | 0.84 | TSHR (0.57) | TSHRHTR2CMAOBCYP2A6PNMT | |
| SCHEMBL4781181 | 0.82 | TSHR (0.62) | TSHRHTR2CMAOBCYP2A6PNMT | |
| SCHEMBL23766 | 0.78 | — | — | |
| SCHEMBL594989 | 0.76 | TSHR (0.46) | TSHRHTR2CMAOBCYP2A6PNMT | |
| SCHEMBL862128 | 0.73 | TSHR (0.56) | TSHRHTR2CMAOBCYP2A6PNMT | |
| SCHEMBL862127 | 0.73 | TSHR (0.56) | TSHRHTR2CMAOBCYP2A6PNMT | |
| SCHEMBL29351986 | 0.71 | — | — | |
| SCHEMBL33555 | 0.71 | — | — | |
| SCHEMBL34906 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1904 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | claimed |
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | claimed |
| WO-2023148206-A1 | MICROBIOCIDAL N-AMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-08-10 | — | — | WO | claimed |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | claimed |
| CN-115867534-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-28 | — | — | CN | claimed |
| EP-4146624-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| EP-4146623-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| CN-115803025-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-14 | — | — | CN | claimed |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2022-09-08 | — | — | US | claimed |
| CN-113234194-B | Copolymer, primer composition, double-layer system and application of double-layer system in double-layer stripping process | 北京科华微电子材料有限公司 | 2022-08-12 | — | — | CN | claimed |
| EP-0512352-A2 | Substituted carboxylic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-11 | — | — | EP | claimed |
| EP-0213080-B1 | HYDROGENATED PYRIDINE DERIVATIVES | CIBA-GEIGY AG (CH) | 1992-05-20 | — | — | EP | claimed |
| EP-0304758-B1 | N,N'-DIACYLAMINALS | BAYER AG (DE) | 1991-09-04 | — | — | EP | claimed |
| US-4987130-A | ANTIARRHYTHMIA AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-01-22 | — | — | US | claimed |
| US-4939160-A | Nootropic agents | CIBA-GEIGY CORPORATION (US) | 1990-07-03 | — | — | US | claimed |
| EP-0335375-A2 | Antihyperlipidemic and antiatherosclerotic compounds and compositions | WARNER-LAMBERT COMPANY (US) | 1989-10-04 | — | — | EP | claimed |
| US-4833169-A | MEMORY ACTIVATORS | CIBA-GEIGY CORPORATION (US) | 1989-05-23 | — | — | US | claimed |
| EP-0286929-A2 | Pyrrolidine derivatives, process for their preparation, agents containing them as well as their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-10-19 | — | — | EP | claimed |
| EP-0213080-A2 | Hydrogenated pyridine derivatives | CIBA-GEIGY AG (CH) | 1987-03-04 | — | — | EP | claimed |
| US-4152527-A | 15-Substituted-ω-pentanorprostaglandins | PFIZER INC. (US) | 1979-05-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | TSHR 3702/4885HTR2C 4681/4885MAOB 1282/4885 |
| US-20220280527-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | TSHR 163/4885HTR2C 208/4885MAOB 454/4885 |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | TSHR 3702/4885HTR2C 4681/4885MAOB 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.